This can result in symptoms like dizziness and light-headedness, especially in people with type 2 diabetes who are taking another medication that lowers glucose levels, like insulin
A similar lower risk for recurrent CUD was observed in patients with and without T2D (Fig
FKK served on scientific advisory panels and/or been part of speaker bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara
[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Lee J.Y., Choi H.Y., Park C.S., Pyo M.K., Yune T.Y., Kim G.W., Chung S.H
Research highlights the benefits of higher doses of semaglutide, such as semaglutide 50 mg, in achieving more substantial weight loss and improved HbA1c levels